Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Rubius Therapeutics (Nasdaq:RUBY) announces that CEO Pablo J. Cagnoni will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. ET. The presentation will showcase Rubius' innovative work in developing Red Cell Therapeutics™, a new class of medicines aimed at treating cancer and autoimmune diseases using the proprietary RED PLATFORM®. A live audio webcast will be available on the company’s website, with an archived replay accessible for 90 days.

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announced today that Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the virtual 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 8:20 a.m. ET.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM^® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Elhan Webb, CFA, Head of Investor Relations
elhan.webb@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
Marissa.hanify@rubiustx.com

Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com

FAQ

When will Rubius Therapeutics present at the J.P. Morgan Healthcare Conference?

Rubius Therapeutics will present on January 13, 2021, at 8:20 a.m. ET.

What is the focus of Rubius Therapeutics' presentation at the conference?

The focus will be on their innovative Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases.

How can I access the Rubius Therapeutics conference presentation?

The presentation will be available via a live audio webcast on Rubius' website.

What is the significance of the RED PLATFORM® developed by Rubius Therapeutics?

The RED PLATFORM® is designed to create potent, off-the-shelf cell therapies for various diseases.

Where can I find more information about Rubius Therapeutics?

Additional information can be found on their official website at www.rubiustx.com.